| Basic Pediatric Series Recommendation for Immunization |
| 4 doses: | 2 months, 4 months, 6 months, 4-6 years |
Note: For adults and catch-up pediatric dosing see CDC recommendations. |
1. What is this vaccine?
This is a vaccine against the polio virus. This vaccine contains 3 strains of inactivated polio virus. It is now preferred over the old oral polio vaccine which contained a live attenuated virus and could lead to some cases of polio itself (vaccine associated paralytic poliomyelitis or VAPP).
2. Why is this vaccine important?
This vaccine can prevent infection with the polio virus which can lead to paralysis or death.
3. How is this vaccine given?
This vaccine is given as a subcutaneous or intramuscular shot, preferably in the mid-lateral thigh in infants and small children and in the deltoid of older children and adults.
4. What are the risks and special considerations of this vaccine?
Serious reactions are unlikely, but some people do get soreness at the injection site. Rare cases of Guillain-Barré have been reported, but causality has not been established. Safety in pregnant women and nursing mothers has not been established.
The recommended regimen is: 1st dose at 2 months of age, 2nd dose at 4 months of age, 3rd dose at 6-18 months of age, and last dose at 4-6 years of age. It is important that the last dose is on or after the 4th birthday and at least 6 months after the prior dose. Also, if 4 doses are given before age 4, a fifth dose should be given between 4 and 6 years of age.
Most adults do not need the shot since they received it as a child. However, a 3-shot series of this vaccine is recommended for adults who have never received the vaccine and are travelling to an endemic area, working with the polio virus, or working with patients who have polio. If these adults did receive 1 or 2 doses in the past, it is recommended that they get the needed 1 or 2 to complete the series. Adults in these groups who did receive 3 shots can get a 4th shot. Check with your doctor.
The vaccine is not recommended for anyone with a history of life threatening reaction to neomycin, streptomycin, or polymyxin B. Individuals with prior severe reactions to this vaccine may not be able to receive another dose. Check with your doctor regarding this issue and for any other contraindications for this vaccine. Also check with your doctor to find out what other ingredients may be in the vaccine, its container, or any diluent in case of allergies or other concerns. Immunization is usually postponed for individuals with a moderate or severe acute illness.
5. Risk factors for contraction of disease
- Children < 5 years old
- Lack of immunity in person travelling to endemic area, working with the polio virus, or working with polio patients
- Lack of immunity in household contact of child receiving OPV
- Immunodeficient patients are at greater risk for paralysis when exposed to poliovirus
Available brands of this vaccine include:
- IPOL®
- Pediarix® (combined with DTaP and Hepatitis B vaccine)
- Pentacel® (combined with DTaP and ActHIB®)
Citations
- "Recommended Immunization Schedule for Persons Aged 0 Through 18 Years --- United States, 2010." MMWR Weekly. Centers for Disease Control and Prevention. January 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5851a6.htm?s_cid=mm5851a6_e.
- "Recommended Adult Immunization Schedule --- United States, 2010." MMWR Weekly. Centers for Disease Control and Prevention. January 2010. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a5.htm?s_cid=mm5901a5.
- "Polio Vaccine What You Need to Know." U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. National Immunization Program. Vaccine Information Statement. January 2000. www.cdc.gov/vaccines/pubs/vis/downloads/vis-IPV.pdf.
- "Polio Immunization (vaccine). Medline Plus. A Service of the U.S. National Library of Medicine and the National Institutes of Health. November 2009. http://www.nlm.nih.gov/medlineplus/ency/article/002030.htm.
- "IPOL: Inactivated Poliomyelitis Vaccine (VERO)." Sanofi Pasteur SA. November 2007. http://www.sanofipasteur.co.nz/sanofi-pasteur/visu.documentheque?codeDocument=189&codeSite=SP_NZ&codeRubrique=50&codeLangue=EN.
- "PEDIARIX® [Diptheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Hepatitis B (Recombinant) abd Inactivated Poliovirus Vaccine Combined]." GlaxoSmithKline. December 2009. http://us.gsk.com/products/assets/us_pediarix.pdf.
- "Diptheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate (Tetanus Toxoid Conjugate) Vaccine: Pentacel®." Sanofi Pasteur. June 2008. http://www.vaccineshoppe.com/image.cfm?pi=510-05&image_type=product_pdf.
- "Vaccine Excipient and Media Summary." U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-1.pdf.
- "Vaccine Excipient and Media Summary, Part 2." U.S. Department of Health and Human Services. Centers for Disease Control and Prevention. April 2009. http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/B/excipient-table-2.pdf.
- "Thimerosol in Vaccines." U.S. Food and Drug Administration. Center for Biologics Evaluation and Research. September 2009. http://www.fda.gov/cber/vaccine/thimerosal.htm.
Created: 7/2/2007
Last Modified: 3/13/2010